tradingkey.logo
tradingkey.logo
Search

Mesoblast Ltd

MESO
Add to Watchlist
14.360USD
+0.070+0.49%
Market hours 10/12, 10:38(ET)
1.86BMarket Cap
LossP/E TTM

Mesoblast Ltd (MESO) Stock Price Target & Forecast

Analyst Rating

Based on 3 analysts giving stock ratings to Mesoblast Ltd in the past month.

Buy
0 Strong Buy
3 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
36.500USD+155.42%

MESO Analyst Recommendation Trends

In the current month, MESO has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MESO average Analyst price target in the last month is 36.500.

2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
Strong Buy
0
0
0
0
0
0
0
0
Buy
3
3
3
3
3
3
3
3
Hold
0
0
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
0
0
Sell
0
0
0
0
0
0
0
0
Total
3
3
3
3
3
3
3
3

MESO Analyst Rating for Peer Comparison

Updated: Oct 11, 2026
Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Ratings
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
14
1
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
IQVIA Holdings Inc
IQV
8
11
3
0
0
22
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Biontech SE
BNTX
4
13
5
0
0
22

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026
Forecast
--
Actual
-0.44
Surprise
--

FAQs

What is Mesoblast Ltd's price target?

Analysts forecast that Mesoblast Ltd's price target is USD 36.50, with the highest forecast at USD 39.00 and the lowest forecast at USD 34.00.

What is the analyst rating for Mesoblast Ltd?

Based on the ratings of Mesoblast Ltd's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.